Training platform accelerates onboarding, expands distribution potential and better positions Company for growth TYLER, Texas / Sep 18, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the launch of Oscar, an advanced training aid, introduced through its ENvue Medical (“ENvue” or “ENvue... Read More

TYLER, Texas / Sep 16, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 291,204 shares of its common stock (or common stock equivalents), at an offering price of $7.01 per... Read More

Latest patent award strengthens competitive moat and reinforces leadership in medical navigation technology TYLER, Texas / Sep 15, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,409,105 B2, titled “Insertion... Read More

Patent strengthens company’s leadership in feeding tube placement and opens path to broader vascular navigation market TYLER, Texas / Sep 04, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled... Read More

Common Stock Will Begin Trading on Split-Adjusted Basis on August 12, 2025 TYLER, Texas / Aug 08, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split... Read More

Upfront $8 Million in Gross Proceeds and potential $40 million in Gross Proceeds from Exercise of Additional Investment Rights TYLER, Texas / Jul 18, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive... Read More

ENvue Targeting $10 Billion+ Market Opportunity with Scalable AI-Enhanced Clinical Robotics TYLER, Texas / Jun 26, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the official launch of a next-generation robotic development initiative within its ENvue Medical (“ENvue” or “ENvue Medical”)... Read More

Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation TYLER, Texas / Jun 24, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue... Read More

Patent strengthens ENvue’s IP position as it advances toward pediatric regulatory clearance and expanded clinical use TYLER, Texas / Jun 11, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its... Read More

TYLER, Texas / Jun 04, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company’s Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC (“ENvue”), a wholly-owned subsidiary of the Company,... Read More

TYLER, Texas / May 28, 2025 / Business Wire / NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is... Read More

Greater New Orleans Area Facility to Transition from Blind Insertions to FDA-Cleared Electromagnetic Guidance TYLER, Texas / May 28, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical”), that a major 420-bed acute care hospital located in... Read More

TYLER, Texas / May 16, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company’s Series G Convertible Preferred Stock (“Preferred Stock”), with a par value $0.001 per share and a stated value equal to $25,... Read More

TYLER, Texas / May 15, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company’s Series G Convertible Preferred Stock (“Preferred Stock”), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of... Read More

UroShield Demonstrates Significant Reductions in CAUTIs, Catheter Blockages and Hospital Visits TYLER, Texas / May 12, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system. The case series,... Read More

ELMSFORD, N.Y. / Apr 11, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million... Read More

Publication of Independent Study Heightens Demand for UroShield ELMSFORD, N.Y. / Apr 01, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. (“Dukehill”). Dukehill, with its Head... Read More

UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs ELMSFORD, N.Y. / Mar 14, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian... Read More

Common Stock Will Begin Trading on Split-Adjusted Basis on March 14, 2025 TYLER, Texas / Mar 12, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split... Read More

ELMSFORD, N.Y. / Feb 14, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. (“ENvue”) (the “Acquisition”), a privately-held, innovative leader in enteral feeding solutions. This strategic transaction will combine the strengths of both... Read More

Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc . (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced a third-party contractor engaged by... Read More

Extends Relationship with Ultra Pain Products, Inc for Distribution of PainShield for Five Years ELMSFORD, N.Y. / Dec 11, 2024 / Business Wire / NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has renewed its exclusive distribution agreement with... Read More

TYLER, Texas / Nov 12, 2024 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on recent business developments. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, “We have made substantial progress over the last... Read More

Signs Term Sheet for a License and Supply Agreement for Distribution of UroShield ELMSFORD, N.Y. / Oct 09, 2024 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement... Read More

ELMSFORD, N.Y. / Sep 23, 2024 / Business Wire / NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD (“Medici”), a leading distributor of medical products in the Israeli healthcare market, to explore... Read More

ELMSFORD, N.Y. / Aug 21, 2024 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments. To Our... Read More

ELMSFORD, N.Y. / May 22, 2024 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The “pilot” phase of the study is the first component of the broader... Read More

TYLER, Texas / May 16, 2024 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments. To Our Stockholders We... Read More

TYLER, Texas / May 14, 2024 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC (“CB Medical”) for the sale and distribution of the Company’s UroShield.... Read More

Distribution Partner, Delta Medical, Awarded a Five-Year Federal Supply Schedule Contract for PainShield by Department of Veterans Affairs ELMSFORD, N.Y. / May 01, 2024 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced... Read More

1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM... Read More

ELMSFORD, N.Y. / Apr 09, 2024 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV)(“NanoVibronix”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business... Read More

Efforts Focused on Adding Therapeutic Functionality and Reducing Costs ELMSFORD, N.Y. / Mar 28, 2024 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. (“Veranex”) to... Read More

UroShield Cited as Effective in Preventing CAUTIs and Blockages and Having a Major Impact on Quality of Life ELMSFORD, N.Y. / Dec 06, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic... Read More

Independent Urology Company to Study the Potential for UroShield Distribution in Germany and other European Markets ELMSFORD, N.Y. / Dec 04, 2023 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the... Read More

Gathering Additional Clinical Evidence to Support Application to FDA for Permanent Clearance ELMSFORD, N.Y. / Nov 28, 2023 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield ® , PainShield ® and WoundShield ® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Research Agreement with the Regents of the University of... Read More

ELMSFORD, N.Y. / Nov 21, 2023 / Business Wire / NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on November 20, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for... Read More

ELMSFORD, N.Y. / Nov 14, 2023 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments. To Our Shareholders... Read More

Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing Demand ELMSFORD, N.Y. / Nov 07, 2023 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV ), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective November 1, its UroShield actuators are eligible for reimbursement... Read More

Establishes Reimbursement for UroShield Actuators Enabling Increased Distribution to NHS Patients NHS Supply Chain Contract Extended for Complete UroShield System ELMSFORD, N.Y. / Sep 27, 2023 / Business Wire / NanoVibronix, Inc. (Nasdaq: NAOV ), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its... Read More

Dr. Sandra Wilks to Present Findings from University of Southampton Study in Toronto ELMSFORD, N.Y. / Sep 06, 2023 / Business Wire / NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that Dr. Sandra Wilks is scheduled to present the findings from her study of UroShield® at... Read More

ELMSFORD, N.Y. / Aug 30, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,906,977 shares of its common stock (or common stock equivalents in lieu... Read More

University of Southampton Study Reports Positive Outcomes in Lab and Patient Testing ELMSFORD, N.Y. / Aug 30, 2023 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today cited positive reported outcomes from a study of UroShield® that was conducted at the University of... Read More

ELMSFORD, N.Y. / Aug 29, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided a response to the recently published payment determination by the Centers for Medicare & Medicaid Services (“CMS”) regarding the company’s PainShield device. On August 21,... Read More

Listing Enables Reimbursement and Increased Distribution for NHS patients ELMSFORD, N.Y. / Aug 28, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on its efforts to expand distribution of its UroShield family of products. In conjunction... Read More

Extension Provides for Guaranteed Purchase Minimums ELMSFORD, N.Y. / Aug 23, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has... Read More

PainShield MD on Exhibit at Mio-Guard Booth #1700 at the National Athletic Trainers’ Association (NATA) Expo ELMSFORD, N.Y. / Jun 14, 2023 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV), a medical device company that produces the UroShield ® , PainShield ® and WoundShield ® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with... Read More

ELMSFORD, N.Y. / May 18, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments. To Our Shareholders:... Read More

ELMSFORD, N.Y. / Apr 18, 2023 / Business Wire / NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company that produces the UroShield ® , PainShield ® and WoundShield ® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a year in review and vision for 2023. To Our Shareholders: NanoVibronix is committed to... Read More

All functionalities proven to be within testing performance criteria ELMSFORD, N.Y. / Mar 28, 2023 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced that independent life expectancy testing performed by Carmel Labs in Israel confirm that its PainShield met all... Read More

ELMSFORD, N.Y. / Mar 21, 2023 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal... Read More

ELMSFORD, N.Y. / Mar 14, 2023 / Business Wire / NanoVibronix, Inc. , (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced the positive evaluation results for its UroShield device, presented at a recent medical conference by clinicians from the Royal National Orthopaedic Hospital (“RNOH”). The report... Read More

ELMSFORD, N.Y. / Mar 03, 2023 / Business Wire / NanoVibronix, Inc . (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on February 28, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for... Read More

ELMSFORD, N.Y. / Feb 22, 2023 / Business Wire / NanoVibronix, Inc . , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it intends to launch a month to month rental program on March 1, 2023 for its lead products, PainShield and UroShield. “Patients with a valid prescription will soon be able to rent PainShield... Read More

ELMSFORD, N.Y. / Feb 08, 2023 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The reverse stock split will become effective at 4:05... Read More

Receives Positive Interim Results of Lifecycle Testing Enactment of Federal ‘NOPAIN Act’ Could Be a Catalyst NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts... Read More